MYBL2 and prostate carcinoma: This study analyzed the expression of MYBL2 across various tumors and found that MYBL2 was significantly upregulated in 20 different cancer types, consistent with previous findings in breast cancer, hepatocellular carcinoma, cervical squamous cell carcinoma, and prostate cancer (31–34).